PolyPid Ltd.

Greetings and welcome to the PolyPEAT second quarter 2024 conference call. At this time, participants are in listen-only mode. As a reminder, this call is recorded, and I would now like to introduce your host for today's conference, Brian Ritchie from LifeSciAdvisors.

Mr. Ritchie, you may begin.

Thank you all for participating in PolyPEAT's second quarter 2024 earnings conference call. Joining me on the call today will be Dikla Chachkis-Axelbred, Chief Executive Officer of PolyPede, Johnny Misalawan, PolyPede's Chief Financial Officer, and Ori Warshawski, Chief Operating Officer, United States of PolyPede. Earlier today, PolyPede released its financial results for the three and six months ended June 30th, 2024. A copy of the press release is available in the Investors section on the company's website, www.polyp.com. I'd like to remind you that on this call, management will make forward-looking statements within the meeting of the federal securities laws. For example, management is making forward-looking statements when it discusses the expected timing for recruitment, number of centers, top-line results from the SHIELD II trial and of the unblinded interim analysis, the planned new drug application submission for DPLEX-100, and the company's expected cash runway and the potential to secure additional funds if all of the warrants issued through its recent pipe are exercised. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. including the risks described from time to time in our SEC filings. Our results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's annual report on Form 20F, which identifies specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. PolyP disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, August 14th, 2024. With the completion of those prepared remarks, it is my pleasure to turn the call over to Dikla Chachkis-Axelbrecht, CEO of PolyPete. Dikla?